Abstract:Malignancy is defined by a set of abnormal biological capacities, termed the hallmarks of cancer. Decades of histopathologic assessment and molecular profiling of human tumors have demonstrated there are multiple ways cells can acquire each hallmark. As a result, tumors with the same clinical characteristics can vary dramatically across individuals and these distinct molecular vulnerabilities can have important prognostic and therapeutic implications. It is unclear when these differences originate. Oncogenic aberrations are acquired within the context of germline genomes which differ across individuals at millions of polymorphic sites, but the role of germline variants in somatic evolution remains poorly understood. The most compelling example is that deleterious germline variants in BRCA1 and, to a lesser extent, BRCA2 are preferentially associated with the development of TNBC, implying germline variants sculpt specific subtypes of disease. The mechanistic basis for this preference is incompletely characterized. Additionally, germline variants that upregulate the mTOR pathway are associated with further deregulation of mTOR via somatic PTEN loss-of-function. Moreover, pathogenic germline variants in cancer predisposition genes promote somatic bi-allelic inactivation in a lineage-dependent manner and rare variants across a diverse list of genes can modulate somatic mutational processes. In prostate cancer, germline variants can modulate genomic stability, tumor-specific DNA methylation and gene regulation at the transcriptional and translational levels. Pathogenic germline variants in genes related to telomere and mitotic function increase the risk of sarcoma. Differences in breast cancer subtype frequencies across ancestral populations further suggest germline contributions. These data point to an underappreciated role of the germline genome in somatic tumor evolution. Various lines of evidence suggest that avoidance of the adaptive immune system is another strong determinant of which somatic mutations persist within a tumor. It remains less clear how germline differences influence immunoediting. Levels of interferon signaling and cytotoxic T-cell infiltration are estimated to be 15-20% heritable. Generally, germline variants have not been considered a good source of immunogenic epitopes as cytotoxic response should be dampened by central tolerance. However, non-mutated immunogenic epitopes have been identified in genes such as ERBB2 in breast and ovarian cancer and H4 histone in prostate cancer, amongst others. Antigens with weak binding affinity for MHC receptors can escape central tolerance and elicit an immune response. Tissue-restricted post-translational modifications can also circumvent central tolerance. Peripheral self-reactive T cells are present at similar frequencies to T cells specific to foreign antigens but are held in an anergic state by regulatory T cells (Treg). However, Treg depletion in healthy mouse models led to the natural occurrence of self-reactive CD4+ T cells. Further, there is mounting evidence for innate-like T-cell populations within mouse and tumor malignancies that have increased propensity for self-reactivity. Altogether, these data suggest that under specific circumstances and disruptions to immune homeostasis, a subset of T-cells may respond to germline-derived epitopes during tumorigenesis. Building on these observations, we sought to investigate whether germline variants sculpt somatic evolution by mediating immunoediting. Specifically, we hypothesize that the burden of germline-derived epitopes in recurrently amplified driver genes may select against gene amplification. This is because amplification of a gene with a high burden of germline-derived epitopes would increase epitope availability, likelihood of epitope presentation and immune-mediated cell death. Instead, immune pressures may select for amplification of an alternate driver gene with a lower germline-mediated epitope burden. Motivation for this hypothesis draws upon insights from the immuno-oncology and population genetics fields. First, in a subset of tumors, somatic tumor mutational burden (TMB), specifically clonal TMB, is positively associated with immunotherapy response. Second, recent successes with cancer vaccines developed from non-somatically mutated, tumor-specific overexpressed peptides, i.e. HER2, TERT and WT1, suggests germline epitopes contribute to immune response. Finally, genome-wide association studies have demonstrated the power of aggregating germline-variants with weak effects into a unified risk score, i.e. polygenic risk score (PRS). Thus, we hypothesized aggregating germline-derived epitopes, with weak individual effects, akin to PRS, may provide a powerful metric to assess germline-mediated immunoediting. We addressed this question in breast cancer for three reasons. First, the well-characterized link be -Abstract Truncated-

Abstract 4093: Modeling tumor immunoediting under immune selective pressure to inform neoantigen landscape dynamics for effective cancer vaccines

Abstract 4107: Evaluating the efficacy of personalized neoantigen cancer vaccine in preclinical model: A promising step towards precision immunotherapy

Abstract 3886: Analysis of clonal heterogeneity within paired primary and metastatic tumor samples of patients with solid tumors and implications for neoantigen-based personalized cancer vaccines

Abstract B045: Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses

Abstract 6738: Overlapping and distinct mechanisms of effective neoantigen cancer vaccines and immune checkpoint therapy

Abstract 4955: An analytic pipeline of neoantigen selection for both MHC-I and MHC-II pathways

Abstract 86: Deep immuno-profiling of syngeneic tumor mouse models for preclinical studies

Abstract B039: Exploring the impact of neoantigen expression on lung tumor development

Abstract 4170: Integrative transcriptomic and proteomic analysis reveals immunogenic and spatially-conserved HLA-binding neoantigen targets derived from tumor-specific alternative splicing events

Abstract 5725: Systematic Identification of Tumour-Specific Neoantigens(by Whole-Genome Sequencing) and Correlation Between Tumour Neoantigen Burden, PD-L1 Expression and Immune Infiltrates in 158asian Colorectal Cancers

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth

Abstract 6539: Bioinformatics Algorithm of Mrna-4157 Identifies Neoantigens with Pre-Existing TIL Reactivities in Colorectal Tumors

Abstract 628: Neoantigens Predicted by Clonal Mutation Analysis in Lung Adenocarcinoma Patients

Integrated Modeling to Implicate Evolving Neoantigen-T Cell Interplays and Immunotherapy Efficacy in Tumors

Abstract NG01: Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity

Abstract 2990: Antigen presentation deficiency and mesenchymal differentiation underlie resistance to immunotherapy in the murine syngeneic CT2A tumor model

Abstract B008: Rescuing neoantigen-specific CD8+ T-cell immunity from tumor- microenvironment-mediated immunosuppression in pancreatic cancer

Cancer neoantigens as potential targets for immunotherapy

Abstract 2088: ATLAS-identified Inhibigen-specific responses accelerate tumor growth in mouse melanoma and pancreatic cancer

Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Abstract A078: Identifying and targeting the genetic determinants of immune suppression and immunotherapy failure in prostate cancer